Warren Pharmaceuticals: Intellectual Assets

IP
Overview

Warren Pharmaceuticals has an established patent strategy aimed at securing exclusivity in the arena of tissue protective cytokine technology. Numerous US and international applications have been filed seeking to protect Warren's novel tissue protective cytokines, and uses of tissue protective cytokines to protect, repair or enhance tissue function.

To date, the U.S. Patent Office has since granted one of these patents, U.S. Patent No. 6,531,121, for the use of tissue protective cytokines based on asialo-erythropoietin to protect, repair and enhance tissue function.

Issued
and
Published
Patents

US Patent or US/PCT Publication Issue / Publication date Title	Summary
U.S. Patent 6,531,121B2 March 11, 2003 Protection and enhancement of erythropoietin-responsive cells, tissues and organs	Methods and compositions are provided for protecting or enhancing erythropoietin-responsive cell, tissue, organ and bodily part function and viability in vivo, in situ or ex vivo in mammals including human beings by systemic or local administration of an erythropoietin receptor activity modulator, such as an erythropoietin
WO0061164 October 19, 2000 Modulation of excitable tissue function by peripherally administered erythropoietin	Methods and compositions are provided for protecting or enhancing excitable tissue function in mammals by systemic administration of an erythropoietin receptor activity modulator, such as erythropoietin, which signals via an EPO-activated receptor to modulate the function of excitable tissue. Excitable tissues include central neuronal tissues, such as the brain, peripheral neuronal tissues, retina, and heart tissue. Protection of excitable tissues provides treatment of hypoxia, seizure disorders, neurodegenerative diseases, hypoglycemia, and neurotoxin poisoning. Enhancement of function is useful in learning and memory. The invention is also directed to compositions and methods for facilitating the transport of molecules across endothelial cell tight junction barriers, such as the blood-brain barrier, by association of molecules with an erythropoietin receptor activity modulator, such as an erythropoietin.
WO0253580A2 July 11, 2002 Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs	Methods and compositions are provided for protecting or enhancing an erythropoietin-responsive cell, tissue, organ or body part function or viability in vivo, in situ or ex vivo in mammals, including human beings, by systemic or local administration of an erythropoietin receptor activity modulator, such as an erythropoietin or a modified erythropoietin.
US2003/0072737A1 April 17, 2003 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs	Methods and compositions are provided for protecting or enhancing a responsive cell, tissue, organ or body part function or viability in vivo, in situ or ex vivo in mammals, including human beings, by systemic or local administration of a tissue protective cytokine
US2003/0104988A1 June 5, 2003 Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs	Methods and compositions are provided for protecting or enhancing an erythropoietin-responsive cell, tissue, organ or body part function or viability in vivo, in situ or ex vivo in mammals, including human beings, by systemic or local administration of an erythropoietin receptor activity modulator, such as an erythropoietin or a modified erythropoietin
US2003/0134798A1 July 17, 2003 Protection and enhancement of erythropoietin-responsive cells, tissues and organs	Methods and compositions are provided for protecting or enhancing erythropoietin-responsive cell, tissue, organ and bodily part function and viability in vivo, in situ or ex vivo in mammals including human beings by systemic or local administration of an erythropoietin receptor activity modulator, such as an erythropoietin
WO0403176 January 8, 2004 Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs	Methods and compositions are provided for protecting or enhancing a responsive cell, tissue, organ or body part function or viability in vivo, in situ or ex vivo in mammals, including human beings, by systemic or local administration of an erythropoietin receptor activity modulator, such as an recombinant tissue protective cytokine.
WO0404656 January 15, 2004 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs	Methods and compositions are provided for treating a mammal having inflammation by protecting or enhancing a responsive cell, tissue, organ or body part exhibiting or associated with the inflammation, by systemic or local administration of a composition comprising a tissue protective cytokine. The invention also encompasses combination treatments comprising administering a composition comprising a tissue protective cytokine of the invention and administering at least one anti-inflammatory or least one immunomodulatory agent.
WO0422577 March 18, 2004 Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin	Methods for increasing the hematocrit of an individual while maintaining the tissue protective activities of endogenous through the administration of a pharmaceutical compound containing chemically modified long acting erythropoietin. Also disclosed are the new chemically modified long acting erythropoietins, methods of producing the chemically modified long acting erythropoietins, and compositions comprising the chemically modified long acting erythropoietins.
WO2004/096148 November 11, 2004 Methods for identifying compounds that have a tissue protective activity using a heteromultimer receptor complex that mediates the tissue protective activities.	The complex consists of at least one EPO-R in complex with at least one ßc Receptor. These compounds used in the assays to identify tissue protective compounds include, but are not limited to, small molecules and biologics. The compounds identified using these assays can be used to treat or prevent various diseases, disorders, or conditions of the central and peripheral nervous systems as well as those of other erythropoietin-responsive or excitable cells, tissues, and organs.
WO2004/112693 December 29, 2004 Tissue protective cytokines with an extended therapeutic window	Methods and uses for a pharmaceutical composition with an erythropoietin or a tissue protective cytokine for protecting or restoring function to a responsive cell, tissue, organ or body part function or viability in mammals when administered outside of the therapeutic window of previously approved therapeutics.
WO2005/025606 March 24, 2005 Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin	Methods for increasing the hematocrit of an individual while maintaining the tissue protective activities of endogenous erythropoietin through the administration of a pharmaceutical compound containing chemically modified long acting erythropoietin. Also disclosed are the new chemically modified long acting erythropoietins, methods of producing the chemically modified long acting erythropoietins, and compositions comprising the chemically modified long acting erythropoietins.
WO2005/032467 April 14, 2005 Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions	A method of treating, preventing, delaying the onset, and/or reducing the effects of proinflammatory cytokines in conditions including, but not limited to, sepsis, adhesion formation, wounds, organ failure, chronic disease, general inflammatory conditions resulting from infection, scarring resulting from injury and incisions, and combinations thereof.
WO 2005/084364 September 15, 2005 Long acting tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs	Methods and compositions are provided for protecting or enhancing a responsive cell, tissue, organ or body part function or viability in vivo, in situ or ex vivo in mammals, including human beings, by systemic or local administration of a long acting tissue protective cytokine. In particular, the long acting tissue protective cytokines of the present invention relate to modified long acting erythropoietins exhibiting a tissue protective effect without an erythropoietic related activity.
WO 2005/117927 December 15, 2005 Tissue protective cytokines with an extended therapeutic window	Methods and uses are provided for a pharmaceutical composition with an erythropoietin or a tissue protective cytokine for protecting or restoring function to a responsive cell, tissue, organ or body part function or viability in mammals when administered outside of the therapeutic window of previously approved therapeutics.
WO 2006/014466 February 9, 2006 Novel carbamylated epo and method for its production	The present invention comprises an optimal process for carbamylation yielding a product with a low degree of polymerisation and aggregation. The fully carbamylated erythropoietin with all of the N-terminal and all lysine residues was obtained. The resulting fully carbamylated pure EPO is along with pharmaceutical compositions comprising the compound are part of the invention.

Return to top of page